Long-term results of the spanish protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children

Clinical and Translational Oncology

Volumn 11, Issue 6, 2009, Pages 387-392

  Muñoz, Arturo ^a   Alfaro, José ^b   Pardo, Nuria ^c   García Miguel, Purificación ^d   Quintero, Víctor ^e   Gros, Luis ^f   Melero, Carmen ^g   Antuña, María Jesús ^h   Ocete, Guillermo ^a   De Las Heras, Jorge ^d   Del Portal, Manuel Ruiz ^b   Huguet, Ramón ⁱ   Maldonado, María Soledad ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Chemotherapy; Children; Osteosarcoma; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOLESCENT; ARTICLE; BONE TUMOR; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE; GENETICS; HUMAN; KAPLAN MEIER METHOD; LIMB; MALE; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PROTO ONCOGENE; SECOND CANCER; SPAIN; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; GENES, MDR; GENES, P53; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; OSTEOSARCOMA; POSTOPERATIVE COMPLICATIONS; SPAIN;

EID: 73349121984     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0373-3     Document Type: Article

References (29)

1. Longhi A, Errani C, De Paolis M et al (2006) Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32:423-436. (Pubitemid 44309249)
2. Bielack S, Carrle D, Jost L (2007) Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 18[SUPPL. 2]:i77-i78.
3. Bielack S, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities and trunk: an analysis of 1702 patients treated with neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol 69:776-790. (Pubitemid 34111386)
4. Glaser DB, Lane JM, Huvos AG et al (1992) Survival, prognosis and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 69:698-708.
5. Bacci G, Ferrari S, Bertoni F et al (2000) Longterm outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Instituto Ortopedico Rizzoli according to the Osteosarcoma- 2 protocol: an updated report. J Clin Oncol 18:4016-4027. (Pubitemid 32038393)
6. Goorin AM, Schwartzentruber DJ, Devidas V et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574- 1580. (Pubitemid 46594112)
7. Ferrari S, Smeland S, Mercuri M et al (2005) Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845-8852. (Pubitemid 46211531)
8. Registro Nacional de Tumores Infantiles. Estadisticas 1980-2007. Universidad de Valencia.
9. Huvos AG (1991) Bone tumors: diagnosis, treatment and prognosis, 2nd Edn. Saunders, Philadelphia, PA.
10. Meyer WH, Pratt CB, Poquette CA et al (2001) Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 19:171- 182. (Pubitemid 32063494)
11. Fuchs N, Bielack S, Epler D et al (1998) Longterm results of the co-operative German- Austrian- Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9:893-899. (Pubitemid 28440449)
12. Winkler K, Bielack SS, Delling G et al (1993) Treatment of osteosarcoma: experience of the Cooperative Group Osteosarcoma Study (COSS). Cancer Treat Res 62:269-277.
13. Brösjo O (1999) Surgical procedure and local recurrence in 223 patients treated 1982-1997 according to two osteosarcoma chemotherapy protocols. The Scandinavian Sarcoma Group Experience. Clin Orthop Relat Res 285:58-61. (Pubitemid 29329081)
14. Petrilli AS, de Camargo B, Fiho VO et al (2006) Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 24:1161-1167.
15. Lindner NJ, Ramm O, Hillmann A et al (1999) Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin Orthop Relat Res 8:3-9.
16. Sluga M, Windhager R, Lang S et al (1999) Local and systemic control after ablative and limb salvage surgery in patients with osteosarcoma. Clin Orthop Relat Res 358:120-127. (Pubitemid 29066081)
17. Bacci G, Forni C, Longhi A et al (2007) Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 96:118-123. (Pubitemid 47264814)
18. Kaste SC, Liu T, Billups CA et al (2004) Tumor size as a predictor of outcome in pediatric nonmetastatic osteosarcoma. Pediatr Blood Cancer 43:723-728. (Pubitemid 39557707)
19. Jun AL, Min SK, Dong HK et al (2008) Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 50:195-200.
20. Papai Z, Feja CN, Hanna EN et al (1997) p53 overexpression as an indicator of overall survival and response to treatment in osteosarcomas. Pathol Oncol Res 3:15-19.
21. Onda M, Matsuda S, Higaki S et al (1996) ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77:71-78. (Pubitemid 26002739)
22. Toguchida J, Yamaguchi T, Ritchie B et al (1992) Mutation spectrum of p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194-6199.
23. Wunder JS, Gokgoz N, Parkes R et al (2005) TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 23:1483-1490.
24. Baldini N, Scotlandi K, Barbanti-Brodano G et al (1995) Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385.
25. Serra M, Maurici D, Scotlandi K et al (1999) Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma. Int J Oncol 14:301-307.
26. Meyers PA, Gorlic R, Heller G et al (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial- Sloan-Kettering (T-12) protocol. J Clin Oncol 16:2452-2458. (Pubitemid 28309040)
27. Reddel RR, Kefford RF, Grant JM et al (1982) Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 66:19-23. (Pubitemid 12254659)
28. Pratt CB, Meyer WH, Luo X et al (1997) Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 80:60-65.
29. Aung L, Gorlik RG, Shi W et al (2002) Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center experience. Cancer 95:1728-1734.